<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316728</url>
  </required_header>
  <id_info>
    <org_study_id>VivaDiag-2020</org_study_id>
    <nct_id>NCT04316728</nct_id>
  </id_info>
  <brief_title>Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19</brief_title>
  <official_title>Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Studi Internazionali, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VivaChek Laboratories, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Studi Internazionali, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to evaluate the immune response of negative patients during a COVID-19
      outbreak.

      Patients are serially tested with a VivaDiag ™ COVID-19 lgM / IgG Rapid Test to evaluate the
      immune response in negative patients and the reliability of the test in those patients who
      develop clinical signs of COVID-19 during the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aim to evaluate the immune response of negative patients during a COVID-19
      outbreak in patients with no symptoms and with no known exposure to the COVID-19.

      Patients are tested with a VivaDiag ™ COVID-19 lgM / IgG Rapid Test at day 0, day 7 and day
      14. The investigators expect test to be negative on all the measurements in those patients
      that do not develop symptoms and that continue to have no known history of exposure to
      COVID-19

      Patients that develop symptoms (cough, fever or respiratory distress) and a possible contact
      with people positive for COVID-19 OR patients that show a positive VivaDiag test during the
      time frame of the test are asked to attend the COVID-19 RT - PCR &amp;CT.

      Subsequently, the investigators will continue, repeating two tests seven days apart every 30
      days (predefined times 0-7-14, then 30-37, 60-67) for the next six months. The investigators
      can evaluate to stop the test however before the six months if there are no new cases of
      COVID-19 for at least 21 days in the region where the enrolled patients live.

      The test in use is the VivaDiag ™ COVID-19 lgM / IgG

      Procedure (as per the protocol in use for the administration of the test)

        1. take out the test kit and leave it at least 30 minutes in the room where the test will
           be performed.

        2. place the test equipment on a clean and dust-free surface

        3. First insert 10µL of whole blood or serum or plasma in the area reserved for blood (in
           the well) present on the test, then apply 2 drops of buffer.

        4. read the result after 15 minutes

      Interpretation of test results

      Positive result

        1. The anti-COVID-19 lgM antibody is detected if: the quality control band C and the lgM
           band are both colored and the lgG band does not stain. This means that the anti-COVID-19
           lgM antibody is positive.

        2. The anti-COVID-19 lgG antibody is detected if: the quality control band C and the lgG
           band are both colored and the lgM band does not stain. This means that the COVID-19 lgG
           antibody is positive.

        3. The lgG and lgM anti-COVID-19 antibodies are detected if: the C band, the lgG band and
           the lgM band are all three colored. This means that the anti-COVID-19 lgG and lgM
           antibodies are both positive.

      Negative result The anti-COVID-19 lgG and lgM antibodies are not detected if only the quality
      control C band is stained but the lgG and lgM bands are not colored, this means that the test
      is negative.

      Invalid result

      If the quality control band C does not color, regardless of whether the lgG and lgM bands are
      colored or not, the result is invalid and the test must be started again.

      Specs of the test

      Product Name VivaDiag™ COVID-19 IgM/IgG Rapid Test Test Principle Colloidal gold Sample Type
      Whole blood (from vein or fingertip), serum or plasma Sample Volume 10 μL Test Time 15 min
      Operation Temperature 18-25ºC Storage Temperature 2-30ºC Shelf Life (Unopened) 12 months
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with constant negative results</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with negative results in the three measurements, compared to the number of patients with at least one positive test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with positive test with a positive PCR for COVID-19</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that present at least one positive VivaDiag test that when subsequently tested with PCR remain positive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Number of patients positive for COVID-19</measure>
    <time_frame>six months</time_frame>
    <description>Where available, number of patients positive for COVID-19 IgG and IgM and positive for COVID-19 PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Number of patients negative for COVID-19</measure>
    <time_frame>six months</time_frame>
    <description>Where available, number of patients negative for COVID-19 IgG and IgM and negative for COVID-19 PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with contrasting results</measure>
    <time_frame>30 days</time_frame>
    <description>Where available, number of patients positive for COVID-19 IgG and IgM and negative for COVID-19 PCR, or negative for COVID-19 IgG and IgM and positive for COVID-19 PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reliability of the test</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Invalid results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive HCW</measure>
    <time_frame>60 days</time_frame>
    <description>Number of healthcare workers that become positive for COVID-19 IgM or IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Chronic Patients</measure>
    <time_frame>60 days</time_frame>
    <description>Number of Chronic Patients that become positive for COVID-19 IgM or IgG</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronavirus Infections</condition>
  <arm_group>
    <arm_group_label>negative Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VivaDiag™ COVID-19 lgM/IgG Rapid Test</intervention_name>
    <description>VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma</description>
    <arm_group_label>negative Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults healthcare workers (HCW) OR

          -  Chronic patients with at least 2 chronic medical conditions

        Exclusion Criteria:

          -  People that have been in contact with people positive for COVID-19 in the previous 14
             days

          -  People with body temperature &gt;37.5°C

          -  People with Dry cough

          -  People with Respiratory distress (Respiratory Rate &gt;25/min or O2 Saturation &lt;92%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Cipolla, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical director of UCCP CATANZARO, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio V Gaddi, MD, MSc</last_name>
    <phone>+393920039246</phone>
    <email>antonio.gaddi@ehealth.study</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio V Capello, MD, PhD</last_name>
    <email>fabio.capello@ehealth.study</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unità' Complesse di cure primarie (UCCP), ASP Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maurizio Cipolla, MD</last_name>
      <email>maurizio.cipolla@ehealth.study</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Zarocostas J. What next for the coronavirus response? Lancet. 2020 Feb 8;395(10222):401. doi: 10.1016/S0140-6736(20)30292-0.</citation>
    <PMID>32035538</PMID>
  </reference>
  <reference>
    <citation>Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 29;:.</citation>
    <PMID>31986257</PMID>
  </reference>
  <reference>
    <citation>Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, Nguyen TT, Cao TM, Pham QD. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020 Feb 27;382(9):872-874. doi: 10.1056/NEJMc2001272. Epub 2020 Jan 28.</citation>
    <PMID>31991079</PMID>
  </reference>
  <reference>
    <citation>Perlman S. Another Decade, Another Coronavirus. N Engl J Med. 2020 Feb 20;382(8):760-762. doi: 10.1056/NEJMe2001126. Epub 2020 Jan 24.</citation>
    <PMID>31978944</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020 Jan 24;12(2). pii: E135. doi: 10.3390/v12020135.</citation>
    <PMID>31991541</PMID>
  </reference>
  <reference>
    <citation>Ronco C, Navalesi P, Vincent JL. Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. Lancet Respir Med. 2020 Mar;8(3):240-241. doi: 10.1016/S2213-2600(20)30060-6. Epub 2020 Feb 6.</citation>
    <PMID>32035509</PMID>
  </reference>
  <reference>
    <citation>Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA. 2020 Apr 21;323(15):1502-1503. doi: 10.1001/jama.2020.2783.</citation>
    <PMID>32105304</PMID>
  </reference>
  <reference>
    <citation>Kobayashi T, Jung SM, Linton NM, Kinoshita R, Hayashi K, Miyama T, Anzai A, Yang Y, Yuan B, Akhmetzhanov AR, Suzuki A, Nishiura H. Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19). J Clin Med. 2020 Feb 21;9(2). pii: E580. doi: 10.3390/jcm9020580.</citation>
    <PMID>32098019</PMID>
  </reference>
  <reference>
    <citation>Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, Fung AY, Ng AC, Zou Z, Tsoi HW, Choi GK, Tam AR, Cheng VC, Chan KH, Tsang OT, Yuen KY. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. J Clin Microbiol. 2020 Apr 23;58(5). pii: e00310-20. doi: 10.1128/JCM.00310-20. Print 2020 Apr 23.</citation>
    <PMID>32132196</PMID>
  </reference>
  <reference>
    <citation>Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. Epub 2020 Feb 21. Review.</citation>
    <PMID>32083985</PMID>
  </reference>
  <reference>
    <citation>Xiao Y, Torok ME. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020 May;20(5):523-524. doi: 10.1016/S1473-3099(20)30152-3. Epub 2020 Mar 5.</citation>
    <PMID>32145766</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol. 2020 Jun;92(6):538-539. doi: 10.1002/jmv.25721. Epub 2020 Mar 11.</citation>
    <PMID>32096564</PMID>
  </reference>
  <reference>
    <citation>Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. AJR Am J Roentgenol. 2020 Jun;214(6):1280-1286. doi: 10.2214/AJR.20.22954. Epub 2020 Mar 4.</citation>
    <PMID>32130038</PMID>
  </reference>
  <reference>
    <citation>Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020 Aug;296(2):E32-E40. doi: 10.1148/radiol.2020200642. Epub 2020 Feb 26.</citation>
    <PMID>32101510</PMID>
  </reference>
  <reference>
    <citation>Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis. Int J Infect Dis. 2020 Apr;93:201-204. doi: 10.1016/j.ijid.2020.02.033. Epub 2020 Feb 22.</citation>
    <PMID>32097725</PMID>
  </reference>
  <reference>
    <citation>Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134. doi: 10.1515/cclm-2020-0198.</citation>
    <PMID>32119647</PMID>
  </reference>
  <reference>
    <citation>Binnicker MJ. Emergence of a Novel Coronavirus Disease (COVID-19) and the Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak. Clin Chem. 2020 May 1;66(5):664-666. doi: 10.1093/clinchem/hvaa071.</citation>
    <PMID>32077933</PMID>
  </reference>
  <reference>
    <citation>Habibi R, Burci GL, de Campos TC, Chirwa D, Cinà M, Dagron S, Eccleston-Turner M, Forman L, Gostin LO, Meier BM, Negri S, Ooms G, Sekalala S, Taylor A, Yamin AE, Hoffman SJ. Do not violate the International Health Regulations during the COVID-19 outbreak. Lancet. 2020 Feb 29;395(10225):664-666. doi: 10.1016/S0140-6736(20)30373-1. Epub 2020 Feb 13.</citation>
    <PMID>32061311</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>IgM Test</keyword>
  <keyword>IgG Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Still under development</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12 months</ipd_time_frame>
    <ipd_access_criteria>Still under development</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

